Aura Biosciences reports Q3 2022 net loss of $15.9M; initiates global Phase 3 trial for bel-sar in choroidal melanoma

Aura Biosciences, Inc.

2022-Q3 EPS reported -$1.44

Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.
Research & development expenses $11.3M (+77% YoY); G&A $4.8M (+92% YoY).
Global Phase 3 trial for bel-sar in early-stage choroidal melanoma initiated: 3-arm, masked, ~75 patients, adaptive design.
Positive Phase 2 interim data: tumor growth rate reduction (p=0.0007), 88.9% tumor control rate, favorable safety.
First patient dosed in Phase 1 for NMIBC; initial data expected in 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aura Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Aura Biosciences Inc, (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.